A project from the American Society of Retina SpecialistsSign in to view content
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
- Video
- Published 2024
Related
Category: Hereditary Retinal Disease & Genetics